Further funding - MRC e-Val 2010
MRC e-Val captures information on other funding held by MRC-supported research groups. In particular, the MRC is interested in further funding gained (at least in part) as a result of obtaining MRC support. It also seeks to find out the proportion of additional funding obtained from outside the UK and from the private sector.
Results from MRC e-Val show that, out of the 623 different funding organisations that are represented in the reports, 469 have contributed £10k or more in the four financial years between 2006/07 and 2009/10. This is a combined total of £2.4bn of non-MRC funding. Funding totalling £59.7m was obtained from the private sector, both within and outside the UK. The largest overseas funder is the National Institutes of Health in the USA, contributing £28.5m. This is followed by the Bill & Melinda Gates Foundation contributing £15.8m.
The largest UK single private sector funder is Merck, providing around £20m in this period in support to the MRC Clinical Trials Services Unit in Oxford. This is followed by GlaxoSmithKline which provided a total of £8.2m across a number of MRC-supported groups.
